Interleukin 2 News and Research

RSS
Study reveals differential blood glycoprotein profiles in symptomatic and asymptomatic COVID-19 patients

Study reveals differential blood glycoprotein profiles in symptomatic and asymptomatic COVID-19 patients

9 Mar 2022
Elevated P2X7 receptor levels in COVID-19 patients correlate with disease severity

Elevated P2X7 receptor levels in COVID-19 patients correlate with disease severity

9 Mar 2022
Biomedical characterization of quantitative proteomics in a hospitalized cohort of COVID-19 patients

Biomedical characterization of quantitative proteomics in a hospitalized cohort of COVID-19 patients

8 Mar 2022
Severity-dependent immune mechanisms in the cerebrospinal fluid and plasma of COVID-19 patients

Severity-dependent immune mechanisms in the cerebrospinal fluid and plasma of COVID-19 patients

7 Mar 2022
Study explores COVID-19 vaccine effectiveness in ankylosing spondylitis patients

Study explores COVID-19 vaccine effectiveness in ankylosing spondylitis patients

7 Mar 2022
Diabetes and the mTOR pathway in COVID-19 patients

Diabetes and the mTOR pathway in COVID-19 patients

6 Mar 2022
Combating COVID cytokine storm with targeted nucleic acid therapies

Combating COVID cytokine storm with targeted nucleic acid therapies

6 Mar 2022
CD4 T-cell immunity active six months into COVID-19 convalescence

CD4 T-cell immunity active six months into COVID-19 convalescence

6 Mar 2022
Omicron-specific mRNA vaccine generates immune responses in mice, hamsters and Macaques

Omicron-specific mRNA vaccine generates immune responses in mice, hamsters and Macaques

6 Mar 2022
Study identifies unique features of MIS-C and how the syndrome gets started in children

Study identifies unique features of MIS-C and how the syndrome gets started in children

4 Mar 2022
Using oral blood pressure drug to treat Type 1 diabetes shows benefits for at least two years

Using oral blood pressure drug to treat Type 1 diabetes shows benefits for at least two years

3 Mar 2022
WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

3 Mar 2022
Dual therapeutic potential of zapnometinib against COVID-19

Dual therapeutic potential of zapnometinib against COVID-19

2 Mar 2022
Adenosine receptor agonists provide therapeutic target in mouse SARS-CoV-2 infection

Adenosine receptor agonists provide therapeutic target in mouse SARS-CoV-2 infection

2 Mar 2022
Analyzing transcriptomic landscape of SARS-CoV-2-infected lung cells

Analyzing transcriptomic landscape of SARS-CoV-2-infected lung cells

1 Mar 2022
Effect of mRNA-based COVID-19 vaccination in multiple myeloma patients

Effect of mRNA-based COVID-19 vaccination in multiple myeloma patients

1 Mar 2022
Scientists discover an innate form of immunological memory in the intestine

Scientists discover an innate form of immunological memory in the intestine

28 Feb 2022
T cell responses in inflammatory bowel disease patients on immune-modifying agents after mRNA COVID-19 vaccination

T cell responses in inflammatory bowel disease patients on immune-modifying agents after mRNA COVID-19 vaccination

25 Feb 2022
Interleukin-1 Receptor-Like 2 cytokine accomplishes a dual effect in inflammation and healing

Interleukin-1 Receptor-Like 2 cytokine accomplishes a dual effect in inflammation and healing

24 Feb 2022
Metalloproteinase-dependent entry pathway differentially used by SARS-CoV-2 Delta, Alpha, and Omicron variants

Metalloproteinase-dependent entry pathway differentially used by SARS-CoV-2 Delta, Alpha, and Omicron variants

24 Feb 2022

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback